Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap

Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant attention from industry. Our center sought to rapidly and safely bring industry sponsored pivotal trials to our patients and to prepare for a...

Descripción completa

Detalles Bibliográficos
Autores principales: Locke, Frederick L., Anasetti, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514522/
https://www.ncbi.nlm.nih.gov/pubmed/28716155
http://dx.doi.org/10.1186/s40425-017-0265-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514522/
https://www.ncbi.nlm.nih.gov/pubmed/28716155
http://dx.doi.org/10.1186/s40425-017-0265-y

Ejemplares similares